The incidence of endometrial cancer (EC) is rising ([@bib8]). A major contributor to this rise is the obesity epidemic. Worldwide, the proportion of women with a BMI of 25 kg m^−2^ or greater has increased from 30% to 38% over a 30-year period ([@bib30]), and as many as 34% of all ECs are directly attributable to patients being overweight or obese ([@bib1]). Endometrial cancer ranks highest among all cancers in its association with obesity, with every 5 kg m^−2^ increase in BMI conferring a 1.6-fold increased risk of the disease ([@bib34]; [@bib6]). Women with type 2 diabetes mellitus (T2DM) have a two-fold increased risk of EC compared with non-diabetic women ([@bib16]), and a prospective study found up to 36% of patients with EC have undiagnosed insulin resistance ([@bib4]). The mechanisms underpinning this link between obesity, insulin resistance and endometrial carcinogenesis are incompletely understood.

Metformin is first-line medical therapy for T2DM. Epidemiological data have suggested that diabetic patients taking metformin have a lower incidence of cancer compared with those taking other hypoglycaemic agents ([@bib14]; [@bib25]). Preclinical studies have demonstrated a growth static effect of metformin on breast, prostate, ovarian and EC cell lines, effected both through alterations in glucose metabolism and inhibition of the PI3K-AKT-mTOR signalling pathway ([@bib44], [@bib43]; [@bib5]; [@bib37]). Metformin accumulates in the tumour tissue and activates AMPK, an inhibitor of the mTOR pathway ([@bib44]). The impact of metformin on tumour growth has been assessed *in vivo* using presurgical window studies, where expression of the proliferation marker Ki-67 is measured before and after treatment with metformin in patients awaiting breast ([@bib20]; [@bib3]; [@bib32]), prostate ([@bib22]) and EC surgery ([@bib23]; [@bib29]; [@bib38]). Three previous studies ([@bib23]; [@bib29]; [@bib38]) report that metformin administration reduced Ki-67 expression in endometrial tumours when given for 2--4 weeks before hysterectomy, but all three lacked a contemporaneous control group, and thus one cannot conclusively attribute these changes to metformin.

As a long-term strategy, we wish to develop large trials using metformin in the pre- or postoperative setting in women with EC. Measurement of tumour Ki-67 expression is a useful and readily performed surrogate biomarker assay, but it is nonspecific. The putative cancer-relevant cellular mechanism for metformin offers an opportunity to include tumour biomarkers, such as phospho-4EBP-1 expression, as surrogates of response, but interpretation in human studies is not trivial, and is confounded by many factors, including sample timing in relation to drug administration and tissue handling. Our long-term aim is to test the hypothesis that metformin has a growth inhibitory effect in EC. Given the potential pitfalls listed above, in the present study, our aim was first to establish that metformin is well tolerated in this oncological setting, and then test the hypothesis that short-term metformin use reduces cellular proliferation in women with atypical endometrial hyperplasia (AEH) and endometrioid EC, and additionally assess the feasibility of using related phosphorylated PI3K-AKT-mTOR proteins as tumour end points.

Materials and methods
=====================

Clinical trial study design
---------------------------

This was a non-randomised trial of metformin or no drug taken during the presurgical window period between diagnosis and hysterectomy. Women with biopsy-proven AEH or endometrioid EC scheduled for hysterectomy were eligible to take part. Women with diabetes on hypoglycaemic medication, those with non-endometrioid histology and those on concomitant progesterone therapy were excluded from the study. Women in the metformin group received metformin 850 mg twice daily for 7 to 30 days until the evening before hysterectomy. Women who declined metformin, whose window period was too short (\<7 days) or whose renal function was impaired (eGFR \<45 ml min^−1^ per 1.732) were recruited to the control group, and received no drug ([Figure 1](#fig1){ref-type="fig"}).

Women were recruited from St Mary\'s Hospital, Manchester and Tameside General Hospital between October 2012 and February 2014. All participants gave written, informed consent. Approvals were received from the North West Centre for Research Ethics Committee and the Medicines and Healthcare Products Regulatory Agency (MHRA). The study was prospectively registered on the European (EudraCT 2011-001382-40) and UK (ISRCTN 81570194) clinical trial databases.

Women taking metformin were monitored for toxicity by telephone call. Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events (CTCAE) v.3.0 ([@bib31]). Where gastrointestinal side effects were intolerable, women withheld metformin until they subsided and recommenced at 850 mg daily, followed by 850 mg twice daily when tolerated. A final pill count established cumulative exposure and treatment compliance. The cumulative dose was divided by days on treatment to calculate the average daily dose.

To assess the known effects of metformin on weight and markers of insulin resistance, at baseline and hysterectomy, height, weight and BMI; waist and hip circumference; and fasting blood glucose, insulin, C-peptide, adiponectin, leptin and high-sensitivity C-reactive protein (hsCRP) were measured. The homeostasis model of assessment of insulin resistance index (HOMA-IR) is the product of fasting glucose and insulin by 22.5 ([@bib27]). Tumour samples were taken at recruitment and at hysterectomy for histopathology and immunohistochemistry (IHC) analyses. A blind biopsy was taken at recruitment using a Pipelle endometrial sampling device; the final tumour sample was taken from the hysterectomy specimen, sampled and processed for clinical decision-making according to standard protocols. The diagnostic Pipelle was used as the baseline biopsy when hysterectomy was scheduled for \<7 days\' time or the recruitment biopsy was not obtained or insufficient for analysis. Consultant gynaecological histopathologists assessed all histopathology samples. Histological subtype, grade, stage, depth of myometrial invasion and the presence of lymphovascular space invasion were assessed using the FIGO 2009 Endometrial Cancer Staging System.

Immunohistochemical analysis
----------------------------

The primary end point was change in Ki-67 proliferation index. This was the percentage of tumour nuclei positively stained for Ki-67 at hysterectomy compared with baseline. Automated IHC staining was performed on 4-*μ*m formalin-fixed paraffin-embedded sections using the Leica Bond Max (Leica Biosystems, Wetzlar, Germany) with heat-induced epitope retrieval. The primary antibody, Ki-67 MIB-1 clone (Dako, Carpinteria, CA, USA), was incubated for 60 min at a 1 : 100 dilution. Primary antibody detection was performed using the Refine Detection Kit (Leica Biosystems). The slides were counterstained with haematoxylin. Negative (isotype control) and positive (tonsil) controls were used for quality assurance.

Full slides were digitised using the Leica SCN400 Slide Scanner (Leica Microsystems, Wetzlar, Germany). To reduce bias and heterogeneity, RM selected equivalent areas to be scored on the pre- and postintervention sections using the haematoxylin and eosin slides. She was blinded to treatment group and intensity of staining for Ki-67 in the areas she selected. The Ki-67 proliferation index was determined from \>2000 nuclei scored in \>3 high powered fields (× 20). A semiautomated score was obtained by applying a computerised algorithm (Definiens Developer) to the malignant glands, which had been selected manually ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). The Pipelle baseline sample was a scrape from the tumour surface while the hysterectomy specimen provided full tumour thickness. To reduce the bias inherent to comparing tumour from two different sampling methods, we restricted Ki-67 scoring to the luminal (surface) aspect of the tumour in the hysterectomy specimen. All scoring was performed by two independent scorers (VS, SK) who were blinded to treatment group. The interobserver intraclass correlation coefficient (ICC) was 0.97 (95% CI 0.96, 0.98) and any discrepancies were reviewed together and resolved by consensus agreement.

Secondary end points included phosphorylated proteins from the PI3K-AKT-mTOR pathway and apoptotic markers. Tissue microarrays (TMAs) were created from triplicate cores of equivalent areas in pre- and postintervention biopsies selected by the study histopathologist (RM), who was blinded to treatment group. Automated IHC was performed using the Leica Bond Max (Leica Biosystems) with heat-induced epitope retrieval. The primary antibodies were: (1) phospho-AKT (p-AKT, Ser 473) at 1:50 dilution; (2) phospho-S6 (p-S6, Ser 235/236) at 1:400 dilution; (3) phospho-acetyl-CoA carboxylase (p-ACC, Ser 79) at 1:300 dilution; (4) phospho-4EBP1 (p-4EBP1, Thr 37/46) at 1:800 dilution; (5) PTEN Clone 6H2.1 (Dako) at 1:600 dilution; and (6) cleaved caspase-3 at 1:200 dilution. All antibodies were from Cell Signalling (Beverley, MA, USA), unless otherwise stated.

p53, oestrogen receptor (ER) and progesterone receptor (PR) status were analysed in the clinical histopathology laboratory according to standard protocols using the automated Ventana BenchMark XT (Ventana, Tucson, AZ, USA). The primary antibodies used were: (1) p53 Clone D07 (Leica Biosystems) at 1:50 dilution; (2) ER Clone SP1 (Roche, Basel, Switzerland); and PR Clone 1E2 (Roche). The same horseradish peroxidase-linked secondary antibody (Ventana) was used for all analyses; the chromagens were sequential DAB and copper. The slides were counterstained using haematoxylin and a bluing agent.

p-AKT, p-ACC, p-S6, p-4EBP1, ER and PR staining was assessed by modified *H*-score, the product of area score (proportion of positively stained core, scored 0--6) and intensity of staining score (0=none, 1=mild, 2=moderate, 3=strong). p-AKT, p-ACC and p-S6 staining was assessed in the cytoplasm and nucleus, whereas p-4EBP1, ER and PR were nuclear. PTEN was positive (strong staining of entire section) or negative (\<10% staining of malignant glands despite strong staining of adjacent stroma) ([@bib17]). p53 was 'mutant-like\' if \>50% of the tumour nuclei showed strong staining, when discrete geographical patterns showed strong staining, or when no p53 was found in the entire tumour ([@bib28]; [@bib33]). Cleaved caspase-3 (cc3) staining was scored by Definiens computerised algorithm that detected positive and negative nuclei and generated a cc3-positive index (percentage of cells positive for cc3). These were checked manually in view of the low proportion of cc3-positive cells. All TMA scoring was completed by two independent scorers (VS, SK) who were blinded to time point and treatment group. The interobserver ICCs were all \>0.94 and any discrepancies were reviewed together and resolved by consensus agreement.

Enzyme-linked immunosorbent assay
---------------------------------

Fasting serum glucose, insulin and C-peptide were measured by automated assay according to routine clinical care standard operating procedures. Adiponectin and leptin were measured using a DuoSet ELISA Development Kit (R&D Systems, Abingdon, UK). High-sensitivity CRP was measured by an in-house antibody sandwich ELISA technique with anti-human CRP primary antibodies, calibrators and controls from Abcam (Cambridge, UK). Intra-assay coefficients of variability (CV) were 3%, 5% and 5% for adiponectin, leptin and hsCRP, respectively. Interassay CVs were 9%, 7% and 6%, respectively.

Statistical analysis
--------------------

The study was powered to observe a 20% reduction in Ki-67 following treatment. Assuming a median baseline Ki-67 proliferation index of 50%, a standard deviation of 20% (in house unpublished data) and a correlation of 70% between pre- and postintervention measurements, a sample size of 29 would have 80% power to detect a 20% change in Ki-67 at the *P*=0.05 significance level. We aimed to recruit 30 women to receive metformin, with opportunistic recruitment of as many contemporaneous controls as possible.

Treatment effect was analysed using an analysis of covariance linear regression model, with post-treatment score as the response variable, and baseline score, age, BMI, insulin resistance (HOMA-IR) and treatment group as covariates. The effect of treatment on serum markers of insulin resistance used the same analysis of covariance, but excluded HOMA-IR as a covariate. Correlations were calculated using Spearman\'s rank-sum correlation coefficients. Descriptive statistics, including mean and s.d. for normally distributed data, and median and interquartile range (IQR), for nonparametric data, were used to compare the two groups of patients.

Results
=======

Study population and baseline parameters
----------------------------------------

In total, 28 women received metformin and 12 received no drug in the presurgical window period between diagnosis and hysterectomy ([Figure 1](#fig1){ref-type="fig"}). Baseline demographics are shown in [Table 1](#tbl1){ref-type="table"}. The two groups were evenly matched in age (mean 64 *vs* 68 years) and BMI (mean 35 *vs* 32 kg m^−2^) in the treated and untreated groups, respectively). Eighty percent of all women were overweight or obese. Four had undiagnosed diabetes (fasting serum glucose \>7.0 mmol l^−1^) and 60% were insulin resistant (fasting glucose 6.0--6.9 mmol l^−1^ or HOMA-IR \>2.8). Most women had low-grade, early-stage tumours (22 out of 28 of metformin-treated and 9 out of 12 untreated women, respectively).

Duration and tolerability of metformin treatment
------------------------------------------------

Women received metformin for a median of 20 days (IQR 17, 24). Seventy-five percent of women experienced AEs but 96% of these were scored as grade 1 AEs ([Table 2](#tbl2){ref-type="table"}). Four patients withdrew from the study completely due to unacceptable gastrointestinal side effects. Thirteen others omitted one or more dose to reduce side effects. The median daily dose received was 1573 mg (IQR 1475, 1659).

Effects of metformin on Ki-67 proliferation index
-------------------------------------------------

Baseline Ki-67 levels were similar in the two groups (mean 50.9% (s.d. 17.1%) in the metformin-treated *vs* 55.6% (s.d. 25.1%) in the untreated women) ([Table 3](#tbl3){ref-type="table"}). Baseline Ki-67 was significantly associated with tumour grade (Spearman\'s correlation coefficient 0.37, 95% CI 0.06, 0.62, *P*=0.018; [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). There was also a significant negative correlation between baseline Ki-67 expression and insulin resistance status (HOMA-IR) (Spearman\'s correlation coefficient −0.43, 95% CI −0.66, −0.13, *P*=0.006), but no relationship with BMI, age, stage or treatment group.

Ki-67 proliferation index was 17.2% lower following metformin treatment (adjusted mean difference −17.2% (95% CI −27.4%, −7.0%), *P*=0.002) after adjustment for baseline Ki-67, age, BMI, insulin resistance (HOMA-IR) and change in the untreated women. Each line in [Figure 2A](#fig2){ref-type="fig"} represents the postintervention change in Ki-67 for an individual woman. A lower Ki-67 was observed in 23 out of 28 (82%) women in the metformin group (range −4 to −55%); the remaining five (18%) showed static or higher Ki-67 levels (range 0.6--14%). There was some evidence of an association between the average metformin dose received and change in Ki-67 (Spearman\'s correlation coefficient *r*=−0.37, 95% CI −0.66, 0.01, *P*=0.051; [Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). A nonsignificant correlation was also observed between baseline BMI and Ki-67 proliferation index change with metformin (Spearman\'s correlation coefficient *r*=0.37, 95% CI −0.02, 0.66, *P*=0.054; [Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}), with leaner women showing a greater Ki-67 change post-treatment with metformin than obese women. Five of 12 (42%) untreated women showed modest reductions in Ki-67 between baseline and hysterectomy (range −1 to −7%), but Ki-67 remained static or increased in most (7 out of 12 women (58%) showed a 1--28% increase in Ki-67).

The interval between baseline and hysterectomy was similar for metformin-treated and -untreated women (median 30 days (IQR 22, 43) *vs* 34 days (IQR 28, 39), respectively). The diagnostic biopsy was used as the baseline sample when a recruitment biopsy was not available. When postintervention change in Ki-67 was assessed using diagnostic biopsies as the baseline sample for all patients (*n*=40), the reduction in Ki-67 in metformin-treated women remained significant (mean adjusted difference −16% (95% CI −27, −5%), *P*=0.005).

Effects of metformin on markers of obesity and insulin resistance
-----------------------------------------------------------------

Short-term metformin was associated with improvements in serum markers of insulin resistance and adiposity (median change in fasting glucose −0.3 mmol l^−1^; insulin −7.0 mU l^−1^; HOMA-IR −2.7; and leptin −2.3 ng ml^−1^), but these were not statistically significant after adjusting for changes in the untreated group ([Table 3](#tbl3){ref-type="table"}).

Effects of metformin on phosphorylated mTOR proteins, markers of apoptosis and hormone receptor expression
----------------------------------------------------------------------------------------------------------

There were global reductions in the expression of phosphorylated mTOR pathway proteins in both groups. [Figure 3](#fig3){ref-type="fig"} shows phospho-AKT, phospho-ACC, phospho-S6 and phospho-4EBP1 expression in metformin-treated and -untreated patients at hysterectomy compared with baseline. p-4EBP1 expression was significantly lower in the metformin-treated patients compared with the untreated group (mean adjusted difference in modified *H*-score of −2.30 (95% CI −4.61, −0.06, *P*=0.045)). The change in expression of the other phosphorylated mTOR pathway proteins was not statistically significant for treatment effect.

The baseline rate of apoptosis was very low (mean positive index 0.01 and 0.003 in metformin-treated and -untreated patients, respectively). We found no correlation between apoptotic index and grade of tumour, but there were very few grade 3 tumours (*n*=4 out of 40). The apoptotic index remained stable over time in both groups; there was no significant effect of treatment (mean adjusted difference 0.00052, 95% CI −0.0015, 0.0025, *P*=0.608, not significant). Oestrogen receptor and PR expression was lower in the hysterectomy specimen compared with the diagnostic biopsies of women from both groups. There was no significant effect of treatment.

Discussion
==========

This is the largest study of presurgical metformin treatment in EC conducted to date. A particular strength of the study is the untreated control group, as the variability of serum and tissue biomarkers between diagnosis and hysterectomy has not been studied before. Although not randomised, the two groups were evenly matched in terms of age, BMI, insulin resistance status, tumour grade and stage. We found that Ki-67 expression was stable on sequential biopsies taken before hysterectomy (data not shown) and a significant reduction in Ki-67 expression was only observed at the time of hysterectomy in the metformin-treatment group. By contrast, a reduction in the expression of phosphorylated PI3K-AKT-mTOR pathway proteins was observed at hysterectomy in both the metformin-treated and -untreated women. Hysterectomy specimens were bisected and immersed in formalin within 30 min of resection. This fixation protocol is standard for routine clinical care and achieves adequate preservation of tissue architecture and the expression of stable proteins like Ki-67, but unstable phosphorylation events may be lost. Future studies should consider taking a blinded biopsy at hysterectomy before devascularisation of the uterus; this would allow preservation of unstable phosphorylation events and facilitate the comparison of tumour biomarkers pre/postintervention on sequential biopsies achieved using the same sampling method.

Most of our patients were overweight or obese and the prevalence of undiagnosed T2DM and insulin resistance was striking. These observations are consistent with previous work ([@bib4]; [@bib7]). Cancer clinicians should have heightened awareness that diabetes (known and undiagnosed) is common amongst women with EC. We observed changes in biomarkers of insulin resistance and adiposity between baseline and hysterectomy in both groups. Whilst weight loss and its associated impact on insulin resistance is a recognised consequence of advanced stage cancer ([@bib15]), the majority of our patients had good prognosis tumours diagnosed at an early stage. The mediator of these alterations may therefore be anxiety-induced behavioural change or intentional weight loss in preparation for surgery. Previous window studies in EC ([@bib23]) and breast cancer ([@bib32]) reported significant changes in biomarkers of adiposity and insulin resistance after short-term metformin treatment, but the lack of a control group hinders interpretation of these data. A large randomised window study in breast cancer that adjusted for changes in untreated controls found no effect of metformin on BMI or insulin resistance after four weeks of treatment ([@bib9]). The latter study had a lower prevalence of overweight/obesity (40%) and insulin resistance (27%) compared with that we report here. Other studies have demonstrated a beneficial impact of metformin on BMI and markers of insulin resistance after a full six months\' of treatment in breast cancer patients ([@bib18]) as well as euglycaemic obese healthy women ([@bib41]), suggesting that the lack of demonstrable effect of metformin on biomarkers of adiposity and insulin resistance reflects the short duration of treatment in this study.

Metformin was generally well tolerated, although 4 out of 36 patients withdrew from the study due to gastrointestinal side effects. When treating T2DM, it is standard to commence metformin at a low dose and build up gradually to limit gastrointestinal toxicity. In this study, metformin was commenced at full dose to maximise the total amount of metformin received before hysterectomy. It is not known whether standard diabetic doses of metformin are sufficient for anticancer activity *in vivo*. In preclinical laboratory studies, supradiabetic concentrations of metformin are required to achieve a growth static effect using cancer cell lines ([@bib5]; [@bib37]; [@bib24]). [@bib29] found metformin at concentrations of 1.2--5.1 *μ*mol kg^−1^ in EC, equivalent to ∼20% of circulating serum levels. The effective concentration of metformin in EC is therefore 1/400 lower compared with concentrations required to suppress proliferation *in vitro*. Optimal anticancer doses of metformin to be used in clinical studies have yet to be established. No studies have performed a dose-escalation protocol and previous window studies have given typical diabetic doses of 500--2250 mg metformin per day ([@bib23]; [@bib29]; [@bib38]). In this study, we observed a Ki-67 drop associated with metformin treatment and this was positively correlated with the average daily dose of metformin received. It is interesting to speculate whether higher doses would have had even greater impact. Metformin is not bound to plasma proteins ([@bib40]) and has a very high volume of distribution. The effective circulating dose of metformin may therefore vary with BMI. We found some evidence of this, with greater reductions in post-metformin Ki-67 observed in leaner patients. Based on these data, we hypothesise that higher doses of metformin may achieve superior anticancer effects, particularly in obese and morbidly obese women. There is considerable interindividual variation in glycaemic response to metformin in T2DM, partly explained by genetic differences in organic cation transporter-1 (OCT-1) expression levels in hepatic and skeletal tissue ([@bib19]; [@bib2]). No studies have measured OCT-1 expression levels in EC, but differences in levels may explain why some patients responded to metformin but others did not. Metformin accumulates in endometrial tissue but has a half-life of 6 h; it is not known whether the timing of the last dose of metformin before serum and endometrial sampling affected our results.

The baseline level of apoptosis was very low in this study and there was no correlation with tumour grade. Apoptosis is poorly documented in EC; however, a similar window study investigating the effects of medroxyprogesterone acetate reported comparable low baseline values ([@bib42]). We also found no evidence for a proapoptotic effect of metformin in EC. In preclinical studies using EC cell lines, apoptosis is only induced at much higher concentrations of metformin compared with those required to inhibit cell growth ([@bib5]).

Ki-67 is an established prognostic and predictive biomarker in breast cancer ([@bib11], [@bib13], [@bib12]), but there is little evidence for its use as a surrogate marker in EC. We and others have shown that high-grade tumours have higher Ki-67 levels; tumour grade is an established independent prognostic biomarker in EC. Several studies have found an association between high Ki-67, other biomarkers of poor prognosis in EC and EC-specific mortality ([@bib35], [@bib36]; [@bib39]; [@bib26]), but there is little consensus regarding optimal staining and scoring protocols to generate robust and reproducible data. We have adapted the International guidelines for Ki-67 staining and scoring in breast cancer established by [@bib10] for this study. We developed a protocol for semiautomated scoring that is both reproducible and demonstrates excellent agreement with manual scoring. In breast cancer, a significant Ki-67 drop following short-term treatment with neoadjuvant chemotherapy is predictive of tumour responsiveness to that drug ([@bib11], [@bib13], [@bib12]). Thus, presurgical window studies have been an efficient way of screening novel therapeutic strategies for breast cancer. This trial design also has great potential in EC, as a trial powered to assess the impact of a new drug in the adjuvant setting using recurrence or EC-specific survival as the end point would be extremely expensive to conduct, requiring thousands of participants over many years of follow-up. Furthermore, like the breast, the endometrium lends itself to sampling in the outpatient setting, facilitating the comparison of matched biopsies taken before and after intervention in the presurgical window period.

Our data add to the growing body of evidence supporting biological activity of metformin in EC that may have therapeutic potential. This is an exciting area of research that is likely to produce further evidence over the next few years. feMMe, a phase II randomised clinical trial, is assessing the additional benefit of metformin or weight loss in combination with the levonorgestrel-releasing intrauterine device in non-surgical patients with AEH and early EC ([@bib21]). Another study is assessing the impact of metformin with paclitaxel and carboplatin for advanced stage or recurrent EC. In addition to its therapeutic role, it is interesting to speculate whether metformin could be used for primary prevention of EC in high-risk groups. Reducing insulin resistance, promoting modest weight loss or preventing further weight gain would seem plausible strategies for EC risk reduction in morbidly obese women. A study assessing the impact of short-term treatment with metformin or placebo with or without a lifestyle intervention program designed to achieve weight loss and increase activity levels is underway, using endometrial Ki-67 as the primary end point. The data from these and similar studies are eagerly awaited.

Conclusion
==========

Short-term presurgical metformin treatment is associated with a significant drop in Ki-67 expression in EC. Changes in phosphorylated mTOR proteins and serum markers of insulin resistance are observed to some extent in both groups, emphasising the need for a control group to adjust for the variability of biomarkers over time. Indeed, the phosphorylation status of mTOR proteins in EC at hysterectomy may be more indicative of devascularisation of the uterus than study interventions. Future studies based on tissue end points should compare pre- and postintervention endometrial biopsies taken using the same sampling method and before devascularisation of the uterus.
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![Flow chart showing study enrolment, withdrawals and exclusions. Concerns about starting a new drug with potential gastrointestinal side effects, inability to adhere to strict follow-up procedures and psychological distress at their recent cancer diagnosis were the most common reasons given for declining participation in the study.](bjc2015453f1){#fig1}

![(**A**) Line graph showing the adjusted mean difference in Ki-67 proliferation index in paired pre- and postintervention endometrial tumours from metformin-treated and control patients. (**B** and **C**) Endometrial tumour stained for Ki-67 before (**B**) and after (**C**) treatment with metformin at × 20 magnification.](bjc2015453f2){#fig2}

![Phosphorylation changes in (**A**) AKT, (**B**) ACC, (**C**) S6 and (**D**) 4EBP1 using box and whisker plots representing the median modified *H*-score (middle line) and the first and third quartile from paired pre- and postintervention endometrial biopsies for metformin-treated and control patients. The whiskers represent the maximum and minimum values.](bjc2015453f3){#fig3}

###### Baseline patient and tumour characteristics at recruitment.

                                                                      **Metformin**  **28**            **Control**    **12**               
  ------------------------------------------------------------------ --------------- -------- -------- ------------- -------- -------- --------
  Age (years)                                                             63.6       8.9               67.8            9.2                 
                                                                         *63.5*      *58.0*    *69.5*  *70.0*         *63.5*   *70.5*   *0.17*
  \<50                                                                      1        3.6%              0               0.0%                
  51--60                                                                   10        35.7%             2              16.7%                
  61--70                                                                   11        39.3%             7              58.3%                
  71--80                                                                    5        17.9%             2              16.7%                
  \>80                                                                      1        3.6%              1               8.3%                
  Body mass index (kg m^−2^)                                              35.5       11.3              32.0            5.9                 
                                                                         *34.1*      *26.8*    *42.9*  *33.2*         *27.0*   *34.8*   *0.52*
  \<25                                                                      6        21.4%             2              16.7%                
  25--29.9                                                                  5        17.9%             3              25.0%                
  \>30--39.9                                                                8        28.6%             5              41.7%                
  \>40                                                                      9        32.1%             2              16.7%                
  Waist/hip girth ratio                                                   0.88       0.06              0.86            0.05                
                                                                         *0.86*      *0.84*    *0.93*  *0.87*         *0.82*   *0.89*   *0.37*
  **Smoking habits**                                                                                                                   
  Nonsmoker                                                                13        46.4%             5              41.7%                
  Ex-smoker                                                                10        35.7%             6              50.0%                
  Current smoker                                                            5        17.9%             1               8.3%                
  Daily alcoholic units                                                                                                                    
   0                                                                       14        50.0%             8              66.7%                
   ⩾2                                                                      11        39.3%             3              25.0%                
   \>2                                                                      2        7.1%              1               8.3%                
  HOMA-IR index                                                           4.36       2.75              3.24            2.34                
                                                                         *3.96*      *2.07*    *5.75*  *2.25*         *1.43*   *4.32*   *0.12*
  Insulin resistance (HOMA-IR \>2.8)                                       17        60.7%             5              41.7%                
  **Tumour grade at hysterectomy**                                                                                                     
  AEH                                                                       0        0.0%              2              16.7%                
  G1                                                                       14        50.0%             1               8.3%                
  G2                                                                       13        46.4%             6              50.0%                
  G3                                                                        1        3.6%              3              25.0%                
  **FIGO stage at hysterectomy[b](#t1-fn3){ref-type="fn"}**                                                                            
  1A                                                                       20        71.4%             7              58.3%                
  1B                                                                        3        10.7%             3              25.0%                
  2                                                                         2        7.1%              0               0.0%                
  3                                                                         3        10.7%             0               0.0%                
  Lymphovascular space invasion present[b](#t1-fn3){ref-type="fn"}          8        28.6%             6              50.0%                
  **Myometrial invasion[b](#t1-fn3){ref-type="fn"}**                                                                                   
  \<50%                                                                    22        78.6%             7              58.3%                
  ⩾50%                                                                      6        21.4%             3              25.0%                
  **Follow-up and adjuvant therapy[b](#t1-fn3){ref-type="fn"}**                                                                        
  Clinical follow-up[c](#t1-fn4){ref-type="fn"}                            17        60.7%             6              60.0%                
  Vaginal brachytherapy                                                     3        10.7%             2              20.0%                
  External beam radiotherapy                                                2        7.1%              1              10.0%                
  External beam radiotherapy and chemotherapy                               3        10.7%             1              10.0%                
  Chemotherapy alone[d](#t1-fn5){ref-type="fn"}                             3        3.6%              0               0.0%                
  **ER expression**                                                                                                                    
  Positive                                                                 28        100.0%            11             91.7%                
  Negative                                                                  0        0.0%              1               8.3%                
  **PR expression**                                                                                                                    
  Positive                                                                 28        100.0%            12             100.0%               
  Negative                                                                  0        0.0%              0               0.0%                
  **PTEN expression**                                                                                                                  
  Wild type                                                                19        67.9%             9              75.0%                
  Mutant                                                                    9        32.1%             3              25.0%                
  **P53 expression**                                                                                                                   
  Wild type                                                                27        96.4%             11             91.7%                
  Mutant                                                                    1        3.6%              1               8.3%                

Abbreviations: AEH=atypical endometrial hyperplasia; EC=endometrial cancer; ER=oestrogen receptor; FIGO=International Federation of Gynecology and Obstetrics; PR=progesterone receptor. The italic entries show that certain figures are the median and IQR, whereas the other figures are the mean and s.d.

Wilcoxon\'s rank-sum test used to compare baseline characteristics in metformin-treated and controls.

Two control patients were excluded as the final histology was atypical endometrial hyperplasia.

Two controls did not have cancer in the final hysterectomy specimen and were discharged from clinical follow-up postsurgery.

Two metformin-treated patients received adjuvant chemotherapy alone for concurrent primary ovarian tumours, but would only have received clinical follow-up stage 1A endometrial tumours. Only one patient received chemotherapy alone for EC.

###### AEs experienced by all patients who participated in the metformin-treatment group

  **Summary of AEs experienced by all patients who received metformin treatment**   ***n***   **(%)**
  --------------------------------------------------------------------------------- --------- ----------------
  Patients who received at least one dose of metformin                              35        100
  Patients who developed any AEs                                                    27        77
  Number of AEs                                                                     98        100
   Grade 1 AE                                                                       94        96
   Grade 2 AE                                                                       3         3
   Grade 3 AE                                                                       1         1
  **No. of patients experiencing an AE**                                                      
  Loss of appetite                                                                  4         11
  Nausea/vomiting                                                                   27        77
  Diarrhoea                                                                         24        69
  Abdominal pain                                                                    12        34
  Skin changes                                                                      3         9
  Headache                                                                          3         9
  Fatigue                                                                           2         6
  Bloating                                                                          2         6
  Abnormal baseline bloods                                                          10        29
  Others                                                                            11        31
  Mean patient tolerability scores (0=not tolerable, 10=very tolerable)             29        6.1 (s.d. 2.5)

Abbreviation: AE=adverse events.

###### Change from baseline following intervention

                                            **Metformin**   **Untreated**                                                                                                                      
  --------------------------- ------------ --------------- --------------- ---------- ---------- --------- ---------- --------- --------- ---------- --------- --------- --------- --- --- --- ---
  Ki-67 proliferation index        \%           50.9           (17.1)         37.4      (20.9)     55.6      (25.1)     58.1     (26.2)     −17.2      −27.4     −7.0      0.002               
                                               *49.8*          *40.6*        *60.4*     *34.9*    *25.8*     *53.6*    *60.1*    *36.6*     *76.2*    *60.5*    *46.4*    *79.2*                 
  Body mass index               kg m^−2^        35.5           (11.3)         35.1      (10.9)     32.0      (5.9)      31.9      (6.0)      −0.1      −0.6       0.3      0.53                
                                               *34.1*          *26.8*        *42.9*     *34.4*    *26.4*     *41.9*    *33.2*    *27.0*     *34.8*    *32.6*    *27.1*    *35.2*                 
  Waist/hip girth ratio                          0.9            (0.1)         0.9       (0.1)       0.9      (0.1)       0.9      (0.1)      0.0        0.0       0.0      0.97                
                                                *0.9*           *0.8*        *0.9*      *0.9*      *0.8*     *0.9*      *0.9*     *0.8*     *0.9*      *0.9*     *0.8*     *0.9*                 
  Glucose                      mmol l^−1^        6.0            (1.5)         5.5       (1.3)       5.7      (0.7)       5.3      (0.6)      0.2       −0.4       0.7      0.56                
                                                *5.6*           *5.0*        *6.4*      *5.3*      *4.9*     *5.9*      *5.6*     *5.2*     *6.3*      *5.3*     *5.1*     *5.6*                 
  Insulin                       mU l^−1^        16.0            (9.4)         9.9       (7.1)      12.3      (8.0)       9.6      (4.5)      12.0      −5.9       2.3      0.38                
                                               *14.5*           *9.0*        *20.0*     *7.5*      *5.2*     *13.5*     *8.7*     *6.7*     *16.4*     *8.4*     *6.6*    *11.5*                 
  HOMA-IR                                        4.4            (2.8)         2.5       (2.0)       3.2      (2.3)       2.3      (1.1)      −0.3      −1.5       0.8      0.54                
                                                *4.6*           *2.3*        *5.8*      *1.9*      *1.3*     *2.8*      *2.3*     *1.4*     *4.3*      *2.0*     *1.6*     *2.8*                 
  C-peptide                    pmol l^−1^      1076.1          (482.3)       985.4     (525.3)     896.4    (341.0)     781.0    (461.2)     44.7     −206.2     295.5     0.72                
                                              *1055.0*         *655.0*      *1365.0*   *1000.0*   *560.0*   *1295.0*   *860.0*   *605.0*   *1023.5*   *750.0*   *600.0*   *985.0*                
  Adiponectin                   mg l^−1^         3.3            (1.5)         2.8       (1.1)       3.4      (1.3)       3.1      (1.2)      −0.3      −0.7       0.2      0.21                
                                                *2.6*           *2.3*        *4.6*      *2.5*      *1.9*     *3.6*      *3.1*     *2.3*     *4.2*      *2.6*     *2.3*     *4.1*                 
  Leptin                       ng ml^−1^        54.1           (42.6)         57.9      (46.7)     42.9      (23.0)     45.5     (23.5)      −2.1      −13.2      9.0      0.70                
                                               *55.0*          *19.3*        *82.5*     *52.7*    *20.2*     *84.1*    *42.8*    *21.5*     *63.9*    *43.8*    *27.6*    *63.8*                 
  Ln (hsCRP)                    mg l^−1^         1.3            (1.3)         0.8       (1.4)       0.9      (1.1)       0.6      (1.2)      0.0       −0.8       0.8      0.99                
                                                *1.3*           *0.2*        *1.9*      *1.0*      *0.2*     *1.5*      *1.2*    −*0.2*     *1.7*      *1.0*    −*0.5*     *1.4*                 

Abbreviations: ANCOVA=analysis of covariance; BMI, body mass index; CI=confidence interval; HOMA-IR=homeostasis model of insulin resistance; hsCRP=high-sensitivity C-reactive protein.

The treatment effect (adjusted mean difference) was analysed using an ANCOVA with post-treatment measurement as the response variable and baseline measurement, age, BMI, insulin resistance (HOMA-IR) and treatment arm as covariates. As some data were not normally distributed, median and quartiles are also presented. The italic entries show that certain figures are the median and IQR, whereas the other figures are the mean and s.d.
